4.4 Article

Type 1 diabetes exacerbates blood-brain barrier alterations during experimental epileptic seizures in an animal model

期刊

CELL BIOCHEMISTRY AND FUNCTION
卷 33, 期 5, 页码 285-292

出版社

WILEY
DOI: 10.1002/cbf.3113

关键词

blood-brain barrier; diabetes; epilepsy; cytokines; ZO-1; GFAP

资金

  1. T.C. Halic University
  2. Istanbul University Scientific Research Projects Unit [T-833]

向作者/读者索取更多资源

The aim of this study was to perform the effects of diabetes on the permeability of the blood-brain barrier (BBB) during pentylenetetrazole (PTZ)-induced epileptic attacks. For this propose, the animals were divided into four groups. These groups contained were intact, PTZ-treated, diabetic and PTZ-treated diabetic individuals, respectively. To evaluate the functioning of the BBB, Evans blue was used as a BBB permeability indicator, and the expressions of zonula occludens-1 and glial fibrillary acidic protein involving the functioning of the BBB were determined immunohistochemically. Also, the changes in the release of serum tumour necrosis factor-alpha and interleukin-10 and interleukin-12 were studied by using enzyme-linked immunosorbent assay method. BBB permeability in the seizures under diabetic conditions showed a considerable increase (p<001) in all of the brain we studied. The immunoreactive staining intensity of zonula occludens-1 and glial fibrillary acidic protein was found reduced in the brain regions of diabetic rats (p<001). However, the serum level of tumour necrosis factor-alpha increased in diabetes and diabetes+PTZ groups, and the serum level of interleukin-12 increased significantly in all experimental groups (p<005). In conclusion, diabetes dramatically increases BBB damage during epileptic seizures, and it may be derived from an elevation of paracellular passage. Copyright (c) 2015 John Wiley & Sons, Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Review Biochemistry & Molecular Biology

Long noncoding RNA: An emerging diagnostic and therapeutic target in kidney diseases

Kumaresan Ramanathan, Minale Fekadie, Giri Padmanabhan, Henok Gulilat

Summary: Long noncoding RNAs (lncRNAs) play critical roles in kidney disease development and their dysregulation can lead to various disease processes. Understanding the function and potential application of lncRNAs in kidney disease may provide new diagnostic and therapeutic opportunities. This review provides an overview of lncRNA characteristics, function, and specific studies related to kidney disease treatment.

CELL BIOCHEMISTRY AND FUNCTION (2024)